Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% against the market benchmark within the next six months [4][18]. Core Insights - The company reported a revenue of 3.73 billion (up 18.9% year-on-year) and a net profit of 530 million (up 19.1% year-on-year) for 2024, with a significant increase in non-recurring net profit by 45% [1][4]. - The fourth quarter of 2024 saw a revenue of 940 million (up 35.6% year-on-year) and a net profit of 70.59 million (up 183.8% year-on-year) [1][4]. - The adjustments in the pharmaceutical channel have shown effectiveness, with the pharmaceutical industry segment achieving a revenue of 2.16 billion (up 17.8% year-on-year) and a gross margin of 71.4% [2][3]. Revenue Breakdown - The company's revenue from hemorrhoid treatment products reached 1.59 billion (up 23.2% year-on-year) with a gross margin of 74% [3]. - The medical commercial segment generated 1.25 billion (up 14.8% year-on-year) with a gross margin of 8.7% [2]. - The healthcare services segment achieved a revenue of 450 million (up 30.2% year-on-year) [2]. Product Development - The company has made progress in multiple research projects, including obtaining clinical approval for a new hemorrhoid treatment and registration for eye care medications [3]. - A total of 60 health products have been developed, covering various categories such as cosmetics and medical devices, laying a solid foundation for future market expansion in the health sector [3]. Financial Forecast - The revenue projections for 2025, 2026, and 2027 are 4.21 billion, 4.73 billion, and 5.27 billion respectively, with growth rates of 13%, 12%, and 11% [4]. - Net profit forecasts for the same years are 680 million, 760 million, and 840 million, with growth rates of 29%, 12%, and 10% [4].

Group 1: Fixed Income Plus Funds Tracking - The performance of various Fixed Income Plus funds shows significant differentiation, with stock-type and mixed-type funds experiencing considerable net value fluctuations due to stock market influences, while convertible bond products exhibit more stable net value performance [1][2][14] - From a performance perspective, mixed-type and convertible bond products have increased by 0.5% and 0.48% respectively this year, outperforming stock-type products which have only increased by 0.22% [2][14] - Fixed Income Plus funds have reduced their exposure to growth styles in equity assets while increasing investments in large-cap styles, resulting in a slight overall increase in equity positions [4][21] Group 2: Pure Bond Funds Tracking - The mid-to-long-term pure bond fund index has decreased by 0.29% this year, while the short-term pure bond fund index has increased by 0.13%. In March, pure bond funds consistently increased their exposure to convexity, focusing on a barbell maturity strategy while overall duration and credit risk exposure were reduced [6][37] - The pure bond fund selection strategy has outperformed the mid-to-long-term pure bond fund index, with the selected combination showing a 0.09% excess return this year [7][48] - The risk exposure analysis indicates that pure bond funds have reduced their duration and credit exposure while increasing convexity exposure, reflecting a more risk-averse operational logic [44]

Group 1 - The total IPO financing scale in the A-share market for March 2025 was 54.08 billion yuan, a decrease of 16% month-on-month. The main board raised 16.47 billion yuan, the ChiNext raised 22.25 billion yuan, and the Sci-Tech Innovation Board raised 3.66 billion yuan [2][5][6] - A total of 10 new stocks were issued in March, representing an 11% increase month-on-month, with 3 from the main board, 5 from the ChiNext, and 1 from the Sci-Tech Innovation Board [2][6] - As of the end of March, there were 46 IPO projects approved but not yet issued across all A-share boards, with a total proposed fundraising scale of 776.9 billion yuan [11] Group 2 - The average winning rate for A/B class accounts on the main board in March was 0.0082% and 0.0070%, down 33% and 31% respectively month-on-month. For the ChiNext, the rates were 0.0117% and 0.0100%, down 49% and 52% respectively [17][22] - The average winning rate for A/B class accounts on the Sci-Tech Innovation Board in March was 0.0412% and 0.0407% [23] - The contribution of new stocks to funds with a scale of 1-2 billion yuan was +0.206%, while for those with a scale of 2-3 billion yuan, it was +0.138%. The annualized return for funds in the 8-9 billion yuan range was 0.447% [29][30] Group 3 - In March 2025, a total of 2,963 funds participated in new stock subscriptions, with a total scale of 5.9 trillion yuan. The most numerous were equity mixed funds, totaling 1,165, followed by passive index funds with 664 [31][32] - The distribution of offline subscription limits for new stocks in the past three months was primarily in the [1,2) billion yuan range across various boards [12][14]

Investment Rating - The industry rating is "Outperform the Market," indicating that the overall return of the industry is expected to exceed the market benchmark index by more than 5% in the next 6 months [17]. Core Views - The report emphasizes that the home furnishing sector is primarily driven by domestic demand, with improving fundamentals and low valuations. The report suggests that the industry is at a turning point, with many companies currently valued at historical lows, presenting a buying opportunity [2]. - In the consumer discretionary sector, companies with low exposure to foreign markets are expected to benefit from industry recovery and consumption promotion policies. Specific companies are highlighted for their growth potential [3]. - The paper industry is anticipated to see cost increases due to tariffs on imported wood pulp, which may benefit domestic high-end corrugated paper manufacturers. The report suggests that domestic companies can adjust their supply chains to mitigate cost impacts [4]. - The metal packaging sector is primarily focused on domestic demand, with companies actively exploring Southeast Asian markets. The report predicts that as domestic demand recovers, the industry's profitability is likely to improve [4]. Summary by Sections Home Furnishing - Domestic sales are the main focus, with companies like 欧派家居 (13x PE), 索菲亚 (11x), and 志邦家居 (9x) highlighted for their low valuations and potential for growth. The report notes that the domestic market is showing signs of recovery, particularly in the second-hand housing sector [2]. Consumer Discretionary - Companies such as 晨光股份 (16x), 登康口腔 (31x), and 稳健医疗 (22x) are recommended due to their low foreign sales exposure and strong growth prospects driven by domestic consumption and strategic initiatives [3]. Paper Industry - The report discusses the impact of tariffs on imported wood pulp, suggesting that domestic high-end corrugated paper manufacturers like 山鹰国际 (16x) and 太阳纸业 (11x) may benefit from a potential demand gap created by these tariffs [4]. Metal Packaging - The report highlights that companies like 奥瑞金 (12x) and 昇兴股份 (10x) are primarily focused on domestic sales, with limited foreign exposure. The expectation is that as domestic demand improves, the industry's profitability will also recover [4].

Group 1 - The burden of cancer treatment costs for residents in China remains significant, with inpatient expenses accounting for 87.53% of total cancer treatment costs in 2018, indicating a focus on inpatient medical services [2][8]. - The adjustment of the medical insurance catalog and price reductions have stimulated clinical patient demand, leading to an increase in the variety and expenditure of antitumor and immunomodulatory agents used in hospitals [3][15]. - In 2018, the total cancer treatment costs in China reached 392.462 billion yuan, representing 11.11% of total disease treatment costs, with cancer treatment expenses constituting 83.44% of tumor treatment costs [8][12]. Group 2 - The average medical expense per hospitalization for cancer patients was 27,136.36 yuan in 2021, the highest among all disease categories, with cancer patients typically requiring 6-7 rounds of radiotherapy or chemotherapy post-surgery [10][11]. - The actual reimbursement rates for medical insurance are lower than policy levels, with 2019 reimbursement rates for employee and resident insurance at 75.6% and 59.7% respectively, leading to higher out-of-pocket expenses for cancer patients compared to other diseases [14]. - The number of antitumor and immunomodulatory agents used in hospitals has seen a significant increase, with a 19.05% rise in the number of varieties from 2015 to 2020 [15][21]. Group 3 - The expenditure on antitumor drugs has shown a steady growth trend, with a 53.85% increase in usage amount in sample hospitals from 2014 to 2019, outpacing the growth in the US market [21][25]. - The frequency of antitumor drug usage in hospitals has been on the rise, with a compound annual growth rate of 12.12% from 2014 to 2019, indicating a sustained clinical demand [28][29].

行 业 研 究 华福证券 电子 2025 年 04 月 08 日 行业周观点：我国电子精密制造国际地位不可替代，反制有望提升国产化 渗透率，科技内循环初具成效 投资要点： "对等关税"扰动全球供应链，我国精密制造国际地位不可替代 行 业 定 期 报 告 4 月 2 日特朗普在白宫签署"对等关税"行政令；对等关税中亚洲 关税明显更高，其中越南 46%、泰国 36%、中国 34%、印尼 32%、印 度 26%、韩国 25%、马来西亚 24%、日本 24%。对中国的关税加上 3 月份执行的 20%，累积关税将达到 54%。关税税率变化大概可以简化 为(贸易逆差/进口总额/2)%；美国提升关税主要目的在于减少其巨额贸 易逆差、加速制造业回流、增加关税收入等。具体到电子和半导体领 域，据海关数据 2024 年我国出口至美国的电子类商品金额达 6242 亿 元，占对美出口金额 17%，是对美出口最大商品类别，体现了美国对 我国精密制造领域的依赖；半导体产品出口由于限制因素，出口至美 国的金额偏少仅 276 亿元，对等关税对半导体出口影响较低。鉴于我 国精密制造国际地位不可替代，同时相关企业已提前构筑了全球性供 应链体系， ...

农林牧渔 2025 年 04 月 07 日 业 研 究 农林牧渔 关税反制落地，关注农业板块投资机会 投资要点： 行 华福证券 行 业 定 期 报 告 种植：加征关税提高进口成本，短期农产品价格或上涨。2025 年 4 月 2 日，美国政府宣布对中国输美商品征收"对等关税"。4 月 4 日，中方发出 反制措施，对原产于美国的所有进口商品，在现行适用关税税率基础上加 征 34%关税。在农产品中，我国对美依赖度（自美进口量在国内消费量占 比）较大的品种包括大豆（20%）、棉花（11%）等，关税影响较大。猪肉、 牛肉、鸡肉等自美进口量在消费中占比 1%左右或以下，关税影响相对有限。 具体来看，1）大豆：我国进口大豆以巴西、美国、阿根廷大豆为主，2018 年中美贸易战促使中国企业转向巴西、阿根廷等南美国家采购，我国大豆 对美依赖度已有所下降。2024 年我国自美进口大豆量为 2213 万吨，在国 内总消费中占比约 20%。分国别来看，2024 年在总进口量中美豆占比 21.1%，较 2017 年-13.3pct，巴西豆占比 71.1%，较 2017 年+17.8pct。加征 关税将直接推高美豆进口成本，利好远月大豆、 ...

本周专题：中美关税战升级 供应链本土化预计加速 行 业 研 究 汽车 2025 年 04 月 07 日 中美关税战升级 供应链本土化预计加速 投资要点： 行 业 定 期 报 告 当地时间 4 月 2 日，美国总统特朗普正式宣布了全球对等关税政 策。此举旨在加速特朗普重塑全球经济的计划，标志着特朗普贸易战 的急剧升级。特朗普宣布，将对所有对美有出口的国家征收至少 10% 的基准关税，并对约 60 个国家实施更高的对等关税，包括中国、欧盟、 日本和越南等美国的主要贸易伙伴，以应对与其他国家之间的巨额贸 易逆差。中国将面临 34%的对等关税，这一税率叠加今年已被征收的 20%关税，意味着许多中国商品面临的美国进口关税将远高于 50%。 需要指出的是，加拿大和墨西哥不在此次对等关税列表中，且符合 USMCA（美墨加协定）规则的合格产品也将继续获得关税豁免，同时 上述新的关税措施也不适用于已经受所谓"232 条款"调查影响的部分 产品，如汽车和汽车零部件、钢铁和铝产品、半导体和木材等。特朗 普同时确认，将从 4 月 3 日开始对全球汽车和轻型卡车征收 25%的关 税，并从 5 月 3 日开始对汽车零部件征收关税。 美国 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical industry [1] Core Insights - The overall holding ratio of the pharmaceutical sector by funds has been continuously declining, with non-pharmaceutical active funds underweighting pharmaceuticals again since the first half of 2022 [9][11] - The holding ratio of all public funds in the pharmaceutical sector for the second half of 2024 is 9.6%, a decrease of 1.2 percentage points from the previous period [3][11] - The holding ratio of all active public funds in the pharmaceutical sector is 9.9%, also down by 1.2 percentage points [3][11] - Non-pharmaceutical funds have a holding ratio of 6.0%, down by 0.8 percentage points, with an increased underweight ratio of 0.26% [3][11] Fund Holdings Overview - The holding ratios for different segments within the pharmaceutical industry show varied trends, with Pharma and Bio-Tech seeing increases, while generic drugs and traditional Chinese medicine are declining [5][15] - The top three segments with increased holdings among all public funds are CXO (+3.8%), Pharma (+2.7%), and Biotech (+0.8%) [8][11] - The top three segments with decreased holdings are medical devices (-1.9%), traditional Chinese medicine (-1.9%), and blood products (-1.3%) [8][11] Detailed Fund Type Analysis - Active pharmaceutical funds are overweight in Pharma, Biotech, and CXO, while non-pharmaceutical funds are overweight in Pharma, CXO, and medical devices [8][11] - The total market value of holdings for all public funds in the pharmaceutical sector is led by 恒瑞医药 (CNY 47.7 billion), 迈瑞医疗 (CNY 45.9 billion), and 药明康德 (CNY 37.2 billion) [8][11] - The top five stocks with increased holdings include 药明康德 (+CNY 7.5 billion) and 联影医疗 (+CNY 3.7 billion) [8][11]

华福证券 固收定期研究 2025 年 4 月 6 日 【华福固收】债券利率下行到位了吗？ 债券利率下行到位了吗？ 从短端利率来说，当前市场 7 天资金利率下行至 1.7-1.75%左右，考虑 7 天 OMO 政策利率在 1.5%，不能 排除市场资金利率还有下行空间，而且央行短期降准降息的概率预计也会提升，因此短端利率还有继续 下行的可能性，下行空间的打开根据实际资金利率水平的表现而定，短信用（1.85-1.9%左右）与存单 （1.8%左右）的利差、存单（1.8%左右）与资金利率（1.7%左右）的利差预计会继续保持在较低的正值 水平。考虑到短端利率债水平始终偏低，部分位置依然是负 carry 状态，因此短信用的确定性要高于短 利率，在整体曲线变陡的过程中，信用曲线变陡的胜率会更大一些。 长端利率方面，当前市场情绪偏好，利率处于容易下行状态。但长端利率存在两个问题：1.较平坦的收 益率曲线可能会制约长债利率的下行空间，从曲线形态来看，8-10Y 国债、5-6Y 和 9-10Y 国开受此影响 会相对小一些。但整体来说，长债利率的下行空间也需要资金下行和短端空间打开；2.长债利率是否会 突破年初低点？年初 1.6%的 ...